Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$129.50 USD

129.50
949,567

+1.81 (1.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $129.00 -0.50 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Zacks Investment Ideas feature highlights: HCA Healthcare, DaVita and General Motors

by Zacks Equity Research

HCA Healthcare, DaVita and General Motors have been highlighted in this Investment Ideas article.

Zacks Equity Research

Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy?

by Zacks Equity Research

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ethan Feller headshot

Markets Appear Vulnerable: Hideout in these 3 Top Ranked Defensive Stocks

by Ethan Feller

There are a number of bearish catalysts brewing... is it time to rotate into these defensive names?

Zacks Equity Research

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

by Zacks Equity Research

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Zacks Equity Research

Sight Sciences (SGHT) to Expand in Europe With New Launch

by Zacks Equity Research

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Zacks Equity Research

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

Zacks Equity Research

GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility

by Zacks Equity Research

GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.

Zacks Equity Research

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Zacks Equity Research

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

by Zacks Equity Research

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

Zacks Equity Research

SenesTech (SNES) Expands in the Netherlands With Q-chem Deal

by Zacks Equity Research

SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.

Zacks Equity Research

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

Zacks Equity Research

QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

by Zacks Equity Research

QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.

Zacks Equity Research

National Vision (EYE) Hurt by Business Closure, Macro Woe

by Zacks Equity Research

National Vision's (EYE) impending termination of the long-term partnership with Walmart is likely to significantly impact its business.

Zacks Equity Research

Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

Shaun Pruitt headshot

3 Top-Rated Stocks to Buy After Comfortably Surpassing Earnings Expectations

by Shaun Pruitt

Investors are always looking for stocks of companies that illustrate business operations are stronger than anticipated and here are three to consider.

Debanjana Dey headshot

4 Stocks to Watch in a Resilient Outpatient Home Health Industry

by Debanjana Dey

The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.

Zacks Equity Research

DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

Zacks Equity Research

DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Zacks Equity Research

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

by Zacks Equity Research

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Shaun Pruitt headshot

Time to Buy These High Growth Stocks as Earnings Approach

by Shaun Pruitt

This week's earnings lineup will be highlighted by several growth stocks with none standing out more than Airbnb (ABNB) and DaVita (DVA).